Clinical Scenarios: Treatment Decisions in Non-Small Cell Lung Cancer

Roy S. Herbst, MD, PhD, discusses considerations for frontline immunotherapy in non–small cell lung cancer.

Corey J. Langer, MD, discusses the benefit observed with the continued treatment of atezolizumab following disease progression in patients with advanced non–small cell lung cancer.

In a recent OncLive® Scientific Interchange, Roy S. Herbst, MD, PhD served as the moderator for a discussion on n using immunotherapy (IO) and targeted therapeutics in patients with NSCLC, to discuss factors impacting therapeutic selection and sequencing strategies in NSCLC, and to evaluate and obtain feedback on the evolving landscape of immunotherapy–based regimens in treating the disease.